Ethypharm India, subsidiary of leading French multinational drug delivery company Ethypharm S.A., has announced out-licensing of five new products in different therapeutic segments with Globalpharma Co LLC. Globalpharma is a leading joint venture company in UAE, a subsidiary of Dubai Investment PJC.

This deal comes in quick succession after a similar deal that Ethypharm signed with Globalpharma for development and supply of Cetirizine 10 mg Oro-dispersible tablets last year.

The products include: Paracetamol 500mg Flashtab (Analgesic Antipyretic); Ciprofloxacin Sustained Release 1000mg (Antibiotic); Metformin Sustained Release 1000mg (Antidiabetic); Gliclazide Sustained Release 30mg (Antidiabetic); and Pseudoephedrine Sustained Release 120mg & Cetirizine 5 mg in combination (Antiallergic).

Under the terms of the agreement, Ethypharm India will be responsible for the development and supply of the 5 products; where in return Globalpharma will be responsible for marketing and distribution in Middle East and Gulf countries.

"With this deal, Ethypharm has clearly established a leadership position in the Drug delivery segment of Middle East and Gulf region," said Ajey Kumar, chief executive officer of Ethypharm India.

The Ethypharm India focuses on developing, manufacturing and licensing pharmaceutical products based on optimization of delivery through proprietary technologies, mainly in the oral sustained release formulations. The company has a special focus on pain management, cardiovascular, oncology and CNS branded and generic products. Over the years, Ethypharm has developed more than 50 branded and generic products, based on its core proprietary technologies.

Globalpharma Co. LLC, a leading joint venture Company in UAE, is a subsidiary of Dubai Investment PJC and is a leading marketer of pharmaceutical products in the Gulf Cooperation Council countries.